

Developing lead substance of X family-targeted antibody therapy in treating acute graft-versus-host disease

Sungkyunkwan University School of Medicine



IMMUNOLOGY	Lead
Product Type	Monoclonal antibodies
Indication	Acute graft-versus-host disease
Target	Novel immune modulatory proteins expressed on the surface of activated T cells
MoA(Mechanism of Action)	1) Elimination of activated T cells, 2) Inhibition of T cell activation
Competitiveness	1) Novel targets in first-in-class therapy 2) Targeted Mode of Action to activated alloreactive T cells 3) Efficient Treatment with Fewer Doses 4) Extended Serum Half-Life 5) Minimal Side Effects
Development Stage	Lead
Route of Administration	Intravenous injection